Acorda Therapeutics, Inc. (NASDAQ:ACOR) Files An 8-K Other Events
Item 8.01Other Events
On March 31, 2017, Acorda Therapeutics, Inc. (the Company)
announced that the United States District Court for the District
of Delaware upheld U.S. Patent No. 5,540,938 (the 938 patent),
which pertains to the formulation of AMPYRA (dalfampridine)
Extended Release Tablets, 10 mg and is set to expire in July
2018. The Court invalidated U.S. Patent Nos. 8,663,685 (the 685
patent), 8,007,826 (the 826 patent), 8,440,703 (the 703 patent),
and 8,354,437 (the 437 patent) which pertain to AMPYRA. The
Company will appeal the ruling on these patents. The Company has
developed contingency plans to address its business needs and
objectives in the event of a loss of AMPYRA exclusivity, and will
provide an update after finalizing the implementation timeline. A
copy of the press release is attached as Exhibit 99.1 to this
Current Report on Form 8-K and is incorporated by reference into
this Item.
Item 9.01Financial Statements and Exhibits
(d) Exhibits
|
Exhibit No. |
Description |
|
99.1 |
Press Release dated March 31, 2017 |
About Acorda Therapeutics, Inc. (NASDAQ:ACOR)
Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in the identification, development and commercialization of therapies that restore function and recovers the lives of people with neurological disorders. Its commercial products include Ampyra, Fampyra, Zanaflex Capsules and a generic version of the capsules, Zanaflex tablets and Qutenza. Its research and development programs include CVT-301, Dalfampridine, Plumiaz, Neuregulin Program, Remyelinating Antibodies Program, CVT-427 and Chondroitinase Program. Its Ampyra is an oral drug for the treatment to improve walking in patients with multiple sclerosis. Zanaflex Capsules and tablets are used as short-acting drugs for the management of spasticity. Qutenza is a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. Its pipeline of neurological therapies addresses a range of disorders, including Parkinson’s disease, chronic post-stroke walking deficits and migraine. Acorda Therapeutics, Inc. (NASDAQ:ACOR) Recent Trading Information
Acorda Therapeutics, Inc. (NASDAQ:ACOR) closed its last trading session down -6.08 at 20.67 with 515,297 shares trading hands.
